Cargando…

Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD

Inhaled bronchodilators are central for the treatment of chronic obstructive pulmonary disease (COPD), as they can provide symptom relief and reduce the frequency and severity of exacerbations while improving health status and exercise tolerance. In 2017, glycopyrrolate (GLY) delivered via the eFlow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tashkin, Donald P., Niu, Xiaoli, Sharma, Sanjay, Sanjar, Shahin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497491/ https://www.ncbi.nlm.nih.gov/pubmed/34620878 http://dx.doi.org/10.1038/s41533-021-00255-7

Ejemplares similares

Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
por: Tashkin, Donald P, et al.
Publicado: (2021)

Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD
por: Siler, Thomas M., et al.
Publicado: (2021)

Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD
por: Putcha, Nirupama, et al.
Publicado: (2021)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
por: Ohar, Jill A, et al.
Publicado: (2020)

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies
por: Donohue, James F, et al.
Publicado: (2020)

Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4
por: Ohar, Jill, et al.
Publicado: (2018)

Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies
por: Hanania, Nicola A, et al.
Publicado: (2021)

Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies
por: Tashkin, Donald P., et al.
Publicado: (2019)

In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®
por: Ohar, Jill A., et al.
Publicado: (2020)

Effect of background long-acting beta(2)-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD
por: Kerwin, Edward M, et al.
Publicado: (2018)

Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies
por: Ohar, Jill A, et al.
Publicado: (2019)

A review of nebulized drug delivery in COPD
por: Tashkin, Donald P
Publicado: (2016)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate [Corrigendum]
Publicado: (2021)

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies [Corrigendum]
Publicado: (2020)

Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease
por: Santus, Pierachille, et al.
Publicado: (2017)

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2018)

In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution
por: Pham, Stephen, et al.
Publicado: (2018)

Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease
por: Leaker, Brian R, et al.
Publicado: (2015)

Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies
por: Kerwin, Edward M, et al.
Publicado: (2020)

The use of nebulized pharmacotherapies during the COVID-19 pandemic
por: Sethi, Sanjay, et al.
Publicado: (2020)

Dose selection for glycopyrrolate/eFlow(®) phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies
por: Donohue, James F., et al.
Publicado: (2017)

Nebulized Therapies in COPD: Past, Present, and the Future
por: Barjaktarevic, Igor Z, et al.
Publicado: (2020)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

EFFECT OF DISCONTINUING NEBULIZER MAINTENANCE BROCHODILATOR THERAPY DURING THE COVID-19 PANDEMIC: A RETROSPECTIVE COHORT STUDY OF ELDERLY COPD PATIENTS RESIDING IN LONG-TERM CARE FACILITIES
por: NIU, XIAOLI, et al.
Publicado: (2021)

Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease
por: Pleasants, Roy A.
Publicado: (2018)

Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids
por: van den Berge, Maarten, et al.
Publicado: (2021)

Glycopyrrolate in toxic exposure to ammonia gas
por: Bhalla, A, et al.
Publicado: (2011)

Is nebulized saline a placebo in COPD?
por: Khan, Shahina Y, et al.
Publicado: (2004)

Maintenance Therapy with Nebulizers in Patients with Stable COPD: Need for Reevaluation
por: Terry, Paul D., et al.
Publicado: (2020)

Perceptions and Attitudes of Patients and Their Family Caregivers on Nebulization Therapy for COPD
por: Dumra, Harjit, et al.
Publicado: (2022)

Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol
por: Ganapathy, Vaidyanathan, et al.
Publicado: (2017)

Nebulized corticosteroids in the management of acute exacerbation of COPD
por: Gaude, G. S., et al.
Publicado: (2010)

Effectiveness of treatment with nebulized colistin in patients with COPD
por: Bruguera-Avila, Nuria, et al.
Publicado: (2017)

Impact of Sugammadex Versus Neostigmine/Glycopyrrolate on Perioperative Efficiency
por: Deyhim, Niaz, et al.
Publicado: (2020)

Smoking cessation in COPD: confronting the challenge
por: Tashkin, Donald P.
Publicado: (2021)

Nebulized formoterol: a review of clinical efficacy and safety in COPD
por: Gross, Nicholas J, et al.
Publicado: (2010)

Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US
por: Rajagopalan, Krithika, et al.
Publicado: (2018)

Efficacy of Glycopyrrolate in Primary Hyperhidrosis Patients
por: Lee, Hyun Ho, et al.
Publicado: (2012)

Glycopyrrolate-Induced Black Hairy Tongue
por: Prabha, Neel, et al.
Publicado: (2020)

Preventing and managing exacerbations in COPD – critical appraisal of the role of tiotropium
por: Tashkin, Donald P
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_7eabg6daloprf28anr26omsfjf